Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the need to improve treatment options for patients with FLT3-mutated acute myeloid leukemia (AML). Dr Wang discusses the growing promise of doublet and triplet combination approaches for these patients, and highlights the importance of further investigating their place in the AML treatment landscape. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.